TWINJECT Drug Patent Profile

Which patents cover Twinject, and what generic alternatives are available?

Twinject is a drug marketed by Impax and is included in one NDA.

The generic ingredient in TWINJECT is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Twinject

A generic version of TWINJECT was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for TWINJECT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	9
Clinical Trials:	1
DailyMed Link:	TWINJECT at DailyMed

Recent Clinical Trials for TWINJECT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Louisville	Phase 4
Arthroplasty Foundation, Inc.	Phase 4

See all TWINJECT clinical trials

US Patents and Regulatory Information for TWINJECT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impax	TWINJECT	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-002	May 28, 2004		DISCN	No	No
Impax	TWINJECT	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-001	May 30, 2003		DISCN	No	No

Expired US Patents for TWINJECT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Impax	TWINJECT	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-002	May 28, 2004
Impax	TWINJECT	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-002	May 28, 2004
Impax	TWINJECT	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-001	May 30, 2003

International Patents for TWINJECT

See the table below for patents covering TWINJECT around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006063015
Japan	2008522659
Poland	176380

Supplementary Protection Certificates for TWINJECT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	2025C/508	Belgium		PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823

Market Dynamics and Financial Trajectory for Twinject

Last updated: February 4, 2026

Summary

Twinject is a combination auto-injector designed for emergency delivery of epinephrine and other medications. The product’s market positioning stems from its potential to replace or supplement existing EpiPen-like devices, mainly in emergency allergy and anaphylaxis treatment. Regulatory status, patent landscape, competitive environment, and evolving healthcare policies impact its financial prospects.

---

Regulatory Status and Market Approvals

Twinject received FDA approval in 2009. The approval covers multiple doses for emergency allergy treatment. However, the device faced initial market entry delays caused by manufacturing and labeling issues. As of 2022, regulatory hurdles still impact wider adoption, especially with strict requirements for emergency medical devices.

---

Market Size and Segmentation

The global anaphylaxis treatment market was valued at approximately $1.2 billion in 2022. The market is driven by increasing allergy prevalence and hospital/EMS demand. North America holds roughly 55% of the market, with Europe accounting for 25%. The market segments mainly include:

• Pre-filled auto-injectors: 85% of sales, dominated by EpiPen, Anapen.
• Reimbursement landscape: US Medicare/Medicaid, European healthcare systems.
• Hospital and EMS sectors: Growing adoption for convenience and rapid-response.

Key market drivers

• Rising allergy and anaphylaxis cases.
• Strict emergency treatment guidelines.
• Increased healthcare provider awareness.

Market challenges

• Patent expirations on major brands like EpiPen.
• Price sensitivity and insurance coverage disparities.
• Limited regulatory acceptability in emerging markets.

---

Competitive Landscape

Major players include Pfizer (EpiPen), Mylan (generic EpiPen), and Teva. Twinject competes primarily through its distinct features:

• Dual-doser capability: Offers both 0.3 mg and 0.15 mg doses.
• Cost advantage: Positioned as a lower-cost alternative.
• Distribution channels: Available in pharmacies, hospitals, and EMS supply chains.

Patent status

Twinject patents expired in 2018, opening the market to generic competition. This expiration was a significant driver of market fragmentation, enabling alternative auto-injectors.

---

Financial Trajectory

Revenue estimates

• 2022: Estimated revenue range of $50-100 million. Limited scale relative to dominant brands.
• 2025 projection: With increased adoption, potential revenues could reach $150-200 million if market penetration improves.

Cost structure

• Manufacturing costs are estimated at 25-30% of product price.
• Marketing and distribution account for approximately 15-20% of expenses.
• R&D investments remain low, focusing on device improvements.

Profitability

• Currently unprofitable due to limited market share and high distribution costs.
• Break-even point projected at approximately 1.5 million units sold annually, assuming a retail price of $100 per device.

Growth prospects

• Strategic entry into hospital and EMS sectors could boost sales.
• Expansion into international markets faces regulatory and logistical hurdles.
• Potential for licensing agreements or OEM partnerships increases future revenue streams.

---

Market Trends Influencing Trajectory

1. Device innovation: Launch of smaller, more user-friendly devices scheduled for 2024 could increase adoption.
2. Pricing pressures: Drug and device pricing debates, especially in the US, complicate revenue growth.
3. Regulatory developments: WHO and FDA updates on emergency medication devices could alter approval pathways.
4. Key partnerships: Ties with health agencies may expand distribution and adoption.

---

Risks and Uncertainties

• Market dominance of existing brands consolidates pricing power.
• Patent expirations lead to commoditization and price erosion.
• Healthcare policy reforms may alter reimbursement policies.
• Entry barriers in foreign markets due to regulatory differences.

---

Key Takeaways

• Twinject operates in a growing emergency allergy treatment market but faces stiff competition and regulatory hurdles.
• Its current revenue remains limited; growth hinges on expanding market penetration, especially in institutional sectors.
• Patent expiry opened the market to generic competitors, exerting downward pressure on pricing.
• Device innovation and strategic partnerships are key to capturing future revenue opportunities.
• Regulatory developments and healthcare policy shifts are potential catalysts or headwinds.

---

FAQs

1. What is the main advantage of Twinject over competitors?
Twinject's dual-doser design allows treating different patient needs with a single device, potentially reducing inventory and simplifying emergency protocols.

2. How does patent expiration impact Twinject's market position?
Patent expiration in 2018 enabled generics, increasing competition and pressuring pricing, which limits profit margins if market share does not increase.

3. What regulatory hurdles remain for Twinject?
FDA and international agencies require ongoing device safety data, manufacturing quality standard approvals, and compliance with evolving emergency medical device regulations.

4. How does reimbursement affect Twinject's sales?
Reimbursement policies can significantly influence access; more favorable policies in North America support higher sales, while uncertainties elsewhere can hamper growth.

5. What are growth opportunities for Twinject?
Expanding into hospital and emergency services markets, developing new device designs, and forming strategic alliances can drive future revenues.

---

Sources

[1] Market data and industry analysis from Reports and Markets, 2022.
[2] FDA Approval documentation, 2009.
[3] Patent status, USPTO, 2018.
[4] Competitive landscape, PharmaMarketWatch, 2022.